Overview

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Status:
Recruiting
Trial end date:
2024-04-06
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the context of a first-in-human study. The effect of food on the rate and extent of absorption of a single oral dose of MK-7762 (TBD09) will also be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Bill & Melinda Gates Medical Research Institute
Collaborator:
Merck Sharp & Dohme LLC